Howard W. Robin

2020

In 2020, Howard W. Robin earned a total compensation of $11.2M as President and Chief Executive Officer at Nektar Therapeutics, a 13% increase compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$1,092,000
Option Awards$4,004,108
Salary$1,053,400
Stock Awards$4,996,266
Other$95,775
Total$11,241,549

Robin received $5M in stock awards, accounting for 44% of the total pay in 2020.

Robin also received $1.1M in non-equity incentive plan, $4M in option awards, $1.1M in salary and $95.8K in other compensation.

Rankings

In 2020, Howard W. Robin's compensation ranked 694th out of 13,090 executives tracked by ExecPay. In other words, Robin earned more than 94.7% of executives.

ClassificationRankingPercentile
All
694
out of 13,090
95th
Division
Manufacturing
241
out of 5,621
96th
Major group
Chemicals And Allied Products
77
out of 2,254
97th
Industry group
Drugs
66
out of 1,954
97th
Industry
Pharmaceutical Preparations
49
out of 1,459
97th
Source: SEC filing on April 30, 2021.

Robin's colleagues

We found four more compensation records of executives who worked with Howard W. Robin at Nektar Therapeutics in 2020.

2020

Gil Labrucherie

Nektar Therapeutics

Chief Financial Officer

2020

Jonathan Zalevsky

Nektar Therapeutics

Chief Research and Development Officer

2020

John Northcott

Nektar Therapeutics

Senior Vice President and Chief Commercial Officer

2020

Mark Wilson

Nektar Therapeutics

General Counsel

News

You may also like